AI Article Synopsis
- The study assessed the safety and effectiveness of Polyquad-preserved Travoprost in patients who had been treated with a different preservative, benzalkonium chloride.
- A total of 44 patients were monitored for 6 months, during which their intraocular pressure significantly decreased and their ocular surface health improved.
- Results showed no development of ocular surface disease, along with enhanced tear film stability and reduced corneal staining among the patients treated with PQ-Travoprost.
Article Abstract
Background: To evaluate the safety and tolerability of Polyquad-preserved Travoprost (PQ-Travoprost) in patients previously treated with benzalkonium chloride (BAK)-preserved Latanoprost.
Methods: Cohort 6-month study on open-angle glaucoma or ocular hypertension patients. Complete ophthalmic examination, intraocular pressure (IOP) measurement and ocular surface status (tear film break-up time [TF-BUT], corneal staining and ocular surface disease index [OSDI]) were evaluated at baseline and 6 months later.
Results: A total of 44 patients were enrolled. Median (interquartile range [IQR]) baseline IOP was 18 (15.5 - 21) and 16 (14 - 17) mmHg (p < 0.0001) after 6 months. At baseline, 18 (40.9%) patients presented an IOP of < 18 mmHg, 11 (25%) < 16 mmHg, 2 (4.3%) < 14 mmHg and 1 (2.3%) < 12 mmHg; 6 months later the proportions were 36 (81.8%) (p < 0.0001), 21 (47.7%) (p = 0.00075), 8 (18.2%) (p = 0.0143) and 6 (13.6%) (p = 0.0253). Concerning safety, TF-BUT improved from 8 [IQR 6 - 10] to 10 [IQR 8 - 12] s (p < 0.0001). No eye developed corneal staining; punctate keratitis was absent in 13 (29.5%) patients at baseline and in 31 (70.4%) after 6 months (p < 0.001). OSDI changed from 16 (10 - 30) to 9 (2 - 20).
Conclusions: No patient treated with PQ-Travoprost developed ocular surface disease after 6 months of monotherapy, whereas many patients reached a good IOP control with lower IOP values. Ocular surface status statistically improved when examined by TF-BUT and corneal staining.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14740338.2015.1017467 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Climate change and ocular surface diseases].
Ophthalmologie
January 2025
Klinik für Augenheilkunde, Universitätsklinikum Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Background: The ocular surface is directly exposed to environmental influences. Noxae that have already been identified for the ocular surface are heat, air dryness, pollutant gases, fine dust particles and ultraviolet radiation.
Methods: The current literature was used to investigate the relationship between frequent ocular surface diseases and various environmental factors and to analyze their development over the years.
Chronic Jet Lag Disrupts Circadian Rhythms and Induces Hyperproliferation in Murine Lacrimal Glands via ROS Accumulation.
Invest Ophthalmol Vis Sci
January 2025
Department of Ophthalmology, People's Hospital of Zhengzhou University, Henan Provincial People's Hospital, Zhengzhou, China.
Purpose: Chronic jet lag (CJL) is known to disrupt circadian rhythms, which regulate various physiological processes, including ocular surface homeostasis. However, the specific effects of CJL on lacrimal gland function and the underlying cellular mechanisms remain poorly understood.
Methods: A CJL model was established using C57BL/6J mice.
Differentiating Between Perfluorohexyloctane Ophthalmic Solution and Water-Free Cyclosporine Ophthalmic Solution 0.1% for Dry Eye Disease: A Review of Preclinical and Clinical Characteristics.
Ophthalmol Ther
January 2025
Santa Barbara Eye Care, Santa Barbara, CA, USA.
Perfluorohexyloctane ophthalmic solution (Miebo) and water-free cyclosporine ophthalmic solution 0.1% (Vevye) are recently approved treatments for dry eye disease (DED). Perfluorohexyloctane (PFHO) uses a novel approach to treat evaporative DED, whereas water-free cyclosporine (CsA 0.
View Article and Find Full Text PDFIn Vitro and In Vivo Visualization of Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Using Infrared Emissivity.
Cornea
November 2024
Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY.
Purpose: To visualize the behavior of perfluorohexyloctane (PFHO), an eye drop to treat dry eye disease (DED), on the surface of saline in vitro and on the human ocular surface using infrared emissivity.
Methods: Emissivity videos were used to measure the spreading and disappearance rates of PFHO on saline (with and without mucin for spreading rate) and layered over a 125 nm film of meibum on the surface of saline using a TearView camera. Ocular surface emissivity was videoed in a volunteer without DED before and after instillation of 1 drop of PFHO.
Orbicularis Oculi Transpalpebral Pedicle Flap for the Repair of Laminar Resorption Associated With Osteo-Odonto-Keratoprosthesis.
Cornea
November 2024
Department of Ophthalmology, University of British Columbia, Vancouver, BC, Canada.
Osteo-odonto-keratoprosthesis (OOKP) is a surgical procedure reserved for severe end-stage corneal blindness with a dry, keratinized ocular surface. Late resorption of bone has been described as a complication of this procedure. We present a novel surgical technique to repair laminar resorption associated with OOKP using transpalpebral split-pedicle orbicularis oculi flaps.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!